AFFINITY AND TRANSCRIPTASE TECHNOLOGIES

亲和力和转录酶技术

• 批准号: 2869464
• 负责人: Frederick S Hagen
• 金额: $ 17.24万
• 依托单位: ICOGENEX CORPORATION
• 依托单位国家: 美国
• 财政年份: 1999
• 资助国家: 美国
• 起止时间: 1999-04-01 至 2001-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/2869464
• 关键词: RNA directed DNA polymerase; complementary DNA; enzyme activity; gel electrophoresis; genetic library; method development; neoplasm /cancer genetics; polymerase chain reaction; posttranscriptional RNA processing; translation factor

DESCRIPTION: (Applicant's Description) One out of every three Americans will be afflicted with cancer in their life time. It is a devastating frightening disease which frequently ends in death after much suffering. Progress has been made in the treatment and cures of cancer but the progress has been incremental. Much time, effort, and expense has gone into research to understand and develop a cure for cancer but because of the complexity and resiliency of the disease, no "magic bullet" has been developed. The foregoing research has inspired the National Cancer Institute to develop the goal of obtaining a full set of complete cDNAs from normal, premalignant, and malignant cells to enable the molecular genetic events which predetermine, activate, and maintain malignancies to be determined. Once the differences in transcribed sequences are identified, the structure, activity, and function of the encoded protein(s) will be of prime importance. To provide the greatest utility, the cDNA libraries to be studied should contain complete cDNA clones so that once differences are ascertained, the clones may be directly used for expression and determination of the function of the encoded protein. The present application describes the development of CAP affinity enrichment and enhanced reverse transcriptase technologies which will significantly contribute to the successful establishment of full sets of complete cDNAs of normal and cancerous tissues. PROPOSED COMMERCIAL APPLICATION: NOT AVAILABLE

描述：(应聘者描述)每三个美国人中就有一个会 在他们的一生中饱受癌症的折磨。这是一个毁灭性的可怕 一种疾病，通常在遭受很大痛苦后死亡。已经取得了进展 在癌症的治疗和治愈方面取得了进展，但进展是 递增的。在研究上投入了大量的时间、精力和费用 了解并开发一种治疗癌症的方法，但由于复杂性和 尽管这种疾病具有很强的恢复力，但还没有研制出“灵丹妙药”。前述内容 研究启发了国家癌症研究所制定了 从正常、癌前和癌前病变组织中获得完整的cDNA 恶性细胞使分子遗传事件能够预先决定， 激活并维持恶性程度待定。一旦两国之间的差异 鉴定转录的序列、结构、活性和功能 编码的蛋白质(S)将是最重要的。以提供最大的 实用价值，待研究的文库应包含完整的cDNA克隆 因此，一旦确定了差异，克隆就可以直接用于 编码蛋白的表达和功能测定。这个 本申请描述了CAP亲和富集法的发展和 增强的逆转录酶技术将显著 为成功建立完整的全套DNA做出贡献 正常组织和癌组织。 建议的商业应用：不可用